Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma

LM. Haveman, A. Ranft, H. Vd Berg, A. Smets, J. Kruseova, R. Ladenstein, B. Brichard, M. Paulussen, T. Kuehne, H. Juergens, S. Klco-Brosius, U. Dirksen, JHM. Merks,

. 2019 ; 8 (3) : 1086-1094. [pub] 20190221

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20022852

BACKGROUND: Magnetic resonance imaging (MRI) is the modality of choice for local staging and response evaluation of Ewing sarcoma (EwS). Aim of this study was to determine the relevance of tumor volume response (TVR) in relation to histological response (HisRes) and survival, in order to evaluate if early modification of chemotherapy might be indicated in patients with inadequate TVR. METHODS: Three dimensional (3D)-tumor volume data at diagnosis, during early induction phase (1-3 courses of chemotherapy; n = 195) and/or late induction phase (4-6 courses; n = 175) from 241 localized patients were retrospectively analyzed. A distinction was made between adequate response (reduction ≥67%) and inadequate response (reduction <67% or progression). Correlations between TVR, HisRes, event free survival (EFS), and overall survival (OS) were analyzed using chi-square tests, log-rank tests, and the Cox-regression model. RESULTS: Early adequate TVR, noted in 41% of patients, did not correlate with EFS (P = 0.92) or OS (P = 0.38). During late induction phase 62% of patients showed an adequate TVR. EFS for patients with late adequate TVR was better (78%) than for those with inadequate late TVR (61%) (P = 0.01); OS was 80% and 69% (P = 0.26), respectively. No correlation was found between TVR and HisRes. Multivariate analysis showed that poor HisRes, pelvic location and late inadequate TVR were associated with poor outcome. CONCLUSIONS: Early inadequate TVR does not predict adverse outcome; therefore, changing the treatment to second line chemotherapy is not indicated in case of inadequate early TVR. Late adequate TVR and good HisRes correlate with better EFS; patients with late inadequate TVR might benefit from augmented therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022852
003      
CZ-PrNML
005      
20201214124857.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.2002 $2 doi
035    __
$a (PubMed)30790456
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Haveman, Lianne M $u Emma Children's Hospital, Department of Pediatric Oncology, Academic Medical Center, Amsterdam, The Netherlands. Prinses Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
245    14
$a The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma / $c LM. Haveman, A. Ranft, H. Vd Berg, A. Smets, J. Kruseova, R. Ladenstein, B. Brichard, M. Paulussen, T. Kuehne, H. Juergens, S. Klco-Brosius, U. Dirksen, JHM. Merks,
520    9_
$a BACKGROUND: Magnetic resonance imaging (MRI) is the modality of choice for local staging and response evaluation of Ewing sarcoma (EwS). Aim of this study was to determine the relevance of tumor volume response (TVR) in relation to histological response (HisRes) and survival, in order to evaluate if early modification of chemotherapy might be indicated in patients with inadequate TVR. METHODS: Three dimensional (3D)-tumor volume data at diagnosis, during early induction phase (1-3 courses of chemotherapy; n = 195) and/or late induction phase (4-6 courses; n = 175) from 241 localized patients were retrospectively analyzed. A distinction was made between adequate response (reduction ≥67%) and inadequate response (reduction <67% or progression). Correlations between TVR, HisRes, event free survival (EFS), and overall survival (OS) were analyzed using chi-square tests, log-rank tests, and the Cox-regression model. RESULTS: Early adequate TVR, noted in 41% of patients, did not correlate with EFS (P = 0.92) or OS (P = 0.38). During late induction phase 62% of patients showed an adequate TVR. EFS for patients with late adequate TVR was better (78%) than for those with inadequate late TVR (61%) (P = 0.01); OS was 80% and 69% (P = 0.26), respectively. No correlation was found between TVR and HisRes. Multivariate analysis showed that poor HisRes, pelvic location and late inadequate TVR were associated with poor outcome. CONCLUSIONS: Early inadequate TVR does not predict adverse outcome; therefore, changing the treatment to second line chemotherapy is not indicated in case of inadequate early TVR. Late adequate TVR and good HisRes correlate with better EFS; patients with late inadequate TVR might benefit from augmented therapy.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a klinické rozhodování $7 D000066491
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    12
$a radiografie $7 D011859
650    _2
$a Ewingův sarkom $x diagnóza $x mortalita $x terapie $7 D012512
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ranft, Andreas $u Department of Pediatric Hematology and Oncology, University of Essen, Essen, Germany. Coordinating Center for Clinical Trials, Muenster, Germany.
700    1_
$a Vd Berg, Henk $u Emma Children's Hospital, Department of Pediatric Oncology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Smets, Anne $u Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Kruseova, Jarmila $u Department of Pediatric Oncology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Ladenstein, Ruth $u Children's Cancer Research Institute, Vienna, Austria.
700    1_
$a Brichard, Benedicte $u Saint Luc University Hospital, Department of Pediatric Hematology and Oncology, University of Louvain, Datteln, Belgium.
700    1_
$a Paulussen, Michael $u Witten/Herdecke University, Vestische Kinder- und Jugendklinik, Datteln, Germany.
700    1_
$a Kuehne, Thomas $u Department of Pediatric Oncology and Haematology, University Children Hospital, Basel, Switzerland.
700    1_
$a Juergens, Heribert $u Coordinating Center for Clinical Trials, Muenster, Germany. Department of Pediatric Hematology and Oncology, University Children's Hospital, Muenster, Germany.
700    1_
$a Klco-Brosius, Stephanie $u Department of Pediatric Hematology and Oncology, University of Essen, Essen, Germany. Coordinating Center for Clinical Trials, Muenster, Germany.
700    1_
$a Dirksen, Uta $u Department of Pediatric Hematology and Oncology, University of Essen, Essen, Germany. Coordinating Center for Clinical Trials, Muenster, Germany.
700    1_
$a Merks, Johannes H M $u Emma Children's Hospital, Department of Pediatric Oncology, Academic Medical Center, Amsterdam, The Netherlands.
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 8, č. 3 (2019), s. 1086-1094
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30790456 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124857 $b ABA008
999    __
$a ok $b bmc $g 1595171 $s 1113528
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 8 $c 3 $d 1086-1094 $e 20190221 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options